Pliant Therapeutics To Host Investor Call And Webcast To Discuss Interim Results From INTEGRIS-PSC, A Phase 2a Trial In Patients With Primary Sclerosing Cholangitis
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics, Inc. (NASDAQ:PLRX) will host a conference call and webcast on September 26, 2023, to discuss the interim results from the INTEGRIS-PSC Phase 2a trial. The call will be joined by Gideon Hirschfield, a principal investigator in the trial. The conference call will be webcast online and accessible from Pliant's website. An archived replay of the webcast will be available for 60 days.
September 25, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pliant Therapeutics is set to discuss interim results from its INTEGRIS-PSC Phase 2a trial, which could potentially impact its stock depending on the results.
The announcement of interim results from a clinical trial can have a significant impact on a biotech company's stock. Positive results could drive the stock up, while negative results could lead to a decline. However, without knowing the results, the impact is uncertain.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100